Show simple item record

dc.contributor.authorAltassan, R
dc.contributor.authorRadenkovic, S
dc.contributor.authorEdmondson, AC
dc.contributor.authorBarone, R
dc.contributor.authorBrasil, S
dc.contributor.authorCechova, A
dc.contributor.authorComan, D
dc.contributor.authorDonoghue, S
dc.contributor.authorFalkenstein, K
dc.contributor.authorFerreira, V
dc.contributor.authorFerreira, C
dc.contributor.authorFiumara, A
dc.contributor.authorFrancisco, R
dc.contributor.authorFreeze, H
dc.contributor.authoret al.
dc.date.accessioned2020-10-07T02:59:32Z
dc.date.available2020-10-07T02:59:32Z
dc.date.issued2020
dc.identifier.issn0141-8955en_US
dc.identifier.doi10.1002/jimd.12286en_US
dc.identifier.urihttp://hdl.handle.net/10072/398154
dc.description.abstractPhosphoglucomutase 1 (PGM1) deficiency is a rare genetic disorder that affects glycogen metabolism, glycolysis, and protein glycosylation. Previously known as GSD XIV, it was recently reclassified as a congenital disorder of glycosylation, PGM1‐CDG. PGM1‐CDG usually manifests as a multisystem disease. Most patients present as infants with cleft palate, liver function abnormalities and hypoglycemia, but some patients present in adulthood with isolated muscle involvement. Some patients develop life‐threatening cardiomyopathy. Unlike most other CDG, PGM1‐CDG has an effective treatment option, d‐galactose, which has been shown to improve many of the patients' symptoms. Therefore, early diagnosis and initiation of treatment for PGM1‐CDG patients are crucial decisions. In this article, our group of international experts suggests diagnostic, follow‐up, and management guidelines for PGM1‐CDG. These guidelines are based on the best available evidence‐based data and experts' opinions aiming to provide a practical resource for health care providers to facilitate successful diagnosis and optimal management of PGM1‐CDG patients.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglish
dc.language.isoeng
dc.publisherWileyen_US
dc.relation.ispartofjournalJournal of Inherited Metabolic Diseaseen_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.keywordsd-galactoseen_US
dc.subject.keywordsPGM1-CDGen_US
dc.subject.keywordscongenital disorder of glycosylationen_US
dc.subject.keywordsmanagement guidelinesen_US
dc.subject.keywordsphosphoglucomutase 1 deficiencyen_US
dc.titleInternational consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and managementen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationAltassan, R; Radenkovic, S; Edmondson, AC; Barone, R; Brasil, S; Cechova, A; Coman, D; Donoghue, S; Falkenstein, K; Ferreira, V; Ferreira, C; Fiumara, A; Francisco, R; Freeze, H; et al., International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management, Journal of Inherited Metabolic Disease, 2020en_US
dcterms.dateAccepted2020-07-14
dc.date.updated2020-10-07T02:16:50Z
gro.hasfulltextNo Full Text
gro.griffith.authorComan, Dave J.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record